As of 2025-03-15, the Relative Valuation of Aclaris Therapeutics Inc (ACRS) is (23.34) USD. This relative valuation is based on P/E multiples. With the latest stock price at 1.56 USD, the upside of Aclaris Therapeutics Inc based on Relative Valuation is -1596.3%.
The range of the Relative Valuation is (20.22) - (25.62) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 16.5x - 21.8x | 19.9x |
| Forward P/E multiples | 16.1x - 20.9x | 18.2x |
| Fair Price | (20.22) - (25.62) | (23.34) |
| Upside | -1395.9% - -1742.6% | -1596.3% |
| Date | P/E |
| 2025-03-07 | -1.50 |
| 2025-03-06 | -1.49 |
| 2025-03-05 | -1.51 |
| 2025-03-04 | -1.58 |
| 2025-03-03 | -1.60 |
| 2025-02-28 | -1.63 |
| 2025-02-27 | -1.59 |
| 2025-02-26 | -1.72 |
| 2025-02-25 | -1.68 |
| 2025-02-24 | -1.69 |
| 2025-02-21 | -1.83 |
| 2025-02-20 | -1.89 |
| 2025-02-19 | -1.89 |
| 2025-02-18 | -1.88 |
| 2025-02-14 | -1.90 |
| 2025-02-13 | -1.80 |
| 2025-02-12 | -1.77 |
| 2025-02-11 | -1.80 |
| 2025-02-10 | -1.95 |
| 2025-02-07 | -2.03 |
| 2025-02-06 | -1.99 |
| 2025-02-05 | -2.10 |
| 2025-02-04 | -2.05 |
| 2025-02-03 | -1.96 |
| 2025-01-31 | -2.03 |
| 2025-01-30 | -1.95 |
| 2025-01-29 | -1.93 |
| 2025-01-28 | -1.95 |
| 2025-01-27 | -2.00 |
| 2025-01-24 | -2.05 |
| 2025-01-23 | -2.08 |
| 2025-01-22 | -2.12 |
| 2025-01-21 | -2.12 |
| 2025-01-17 | -2.10 |
| 2025-01-16 | -2.05 |
| 2025-01-15 | -2.05 |
| 2025-01-14 | -2.04 |
| 2025-01-13 | -2.03 |
| 2025-01-10 | -2.02 |
| 2025-01-08 | -2.01 |
| 2025-01-07 | -2.04 |
| 2025-01-06 | -2.07 |
| 2025-01-03 | -2.12 |
| 2025-01-02 | -2.03 |
| 2024-12-31 | -2.03 |
| 2024-12-30 | -2.03 |
| 2024-12-27 | -2.23 |
| 2024-12-26 | -2.38 |
| 2024-12-24 | -2.37 |
| 2024-12-23 | -2.36 |